Mkt Cap$2.23T+3.02%
24h Vol$77.93B
BTC Dom56.1%
ETH Dom8.8%
F&G12Extreme Fear
BTC$62,291.00+3.20% ETH$1,626.48+5.83% USDT$0.9995+0.00% BNB$591.85+3.54% USDC$0.9996+0.00% XRP$1.14+5.57% SOL$64.60+5.18% TRX$0.3286+3.15% FIGR_HELOC$1.03+0.46% HYPE$58.79+0.64% DOGE$0.0843+5.16% USDS$0.9997+0.01% LEO$9.55-0.31% RAIN$0.0134+4.90% XLM$0.2048+5.05% ZEC$398.76+9.00% BTC$62,291.00+3.20% ETH$1,626.48+5.83% USDT$0.9995+0.00% BNB$591.85+3.54% USDC$0.9996+0.00% XRP$1.14+5.57% SOL$64.60+5.18% TRX$0.3286+3.15% FIGR_HELOC$1.03+0.46% HYPE$58.79+0.64% DOGE$0.0843+5.16% USDS$0.9997+0.01% LEO$9.55-0.31% RAIN$0.0134+4.90% XLM$0.2048+5.05% ZEC$398.76+9.00%
RAIN+4.90% Earnings

Danaher (DHR) Beats Q1 Projections with $1.1 B in Net Earnings, $1.92 EPS

Danaher Corporation exceeded market expectations in Q1 2024, reporting net earnings of $1.1 billion and non-GAAP diluted net earnings per common share of $1.92.

Danaher (DHR) Beats Q1 Projections with $1.1 B in Net Earnings, $1.92 EPS
Image courtesy of 123rf.com
Editorial disclosureRead more

All reviews, research, news and assessments of any kind on The Tokenist are compiled using a strict editorial review process by our editorial team. Neither our writers nor our editors receive direct compensation of any kind to publish information on tokenist.com. Our company, Tokenist Media LLC, is community supported and may receive a small commission when you purchase products or services through links on our website. Click here for a full list of our partners and an in-depth explanation on how we get paid.

Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.

Danaher Corporation (NYSE: DHR), a global leader in the life sciences and diagnostics sectors, has reported its financial results for the first quarter ended March 29, 2024.

Despite a challenging economic environment, the company surpassed expectations in terms of revenue and earnings. Danaher announced net earnings of $1.1 billion, translating to $1.45 per diluted common share. The non-GAAP diluted net earnings per common share stood at $1.92 on an adjusted basis. This performance is particularly noteworthy given the reported revenue decrease of 2.5% year-over-year to $5.8 billion, with non-GAAP core revenue decreasing by 4.0%.

Operating cash flow remained robust at $1.7 billion, with non-GAAP free cash flow reaching $1.4 billion. The company’s President and Chief Executive Officer, Rainer M. Blair, expressed satisfaction with the quarter’s results, highlighting the improved order trends in the bioprocessing business and market share gains in the molecular diagnostics business at Cepheid.

Blair emphasized the combination of Danaher’s leading portfolio and the execution of the Danaher Business System as foundational elements for sustained long-term performance and significant contributions to improving human health.

Danaher Comfortably Beats EPS and Revenue Expectations in Q1

Analysts had projected earnings per share (EPS) of $1.72 and revenue of $5.62 billion for the quarter. Danaher’s adjusted EPS of $1.92 significantly exceeded these expectations, showcasing the company’s operational efficiency and ability to generate higher profitability than anticipated.

Similarly, the reported revenue of $5.8 billion surpassed analyst forecasts, indicating more robust sales performance across its diverse portfolio. Despite a year-over-year revenue decline, these results underscore Danaher’s resilience and strategic focus in a competitive landscape.

Better-than-expected financial outcomes can be attributed to several factors, including strong performance in key business segments and effective cost management. The company’s ability to adapt to changing market conditions and leverage the Danaher Business System has enabled it to continue delivering value to shareholders and customers.

Cautious Guidance, Expects Non-GAAP Core Revenue to Decline in Q2

Looking ahead, Danaher guided for the second quarter and full year 2024, with expectations set against ongoing global economic uncertainty.

For the second quarter of 2024, the company anticipates a mid-single-digit decline in non-GAAP core revenue year over year and a low-single-digit decline for the full year. This guidance reflects the company’s cautious outlook in light of potential market volatility and challenges within the global economic environment.

Disclaimer: The author does not hold or have a position in any securities discussed in the article.


Tim Fries

Tim Fries

Author · Tokenist

Tim Fries is the cofounder of The Tokenist. He has a B. Sc. in Mechanical Engineering from the University of Michigan, and an MBA from the University of Chicago Booth School of Business. Tim served as a Senior Associate on the investment team at RW Baird's US Private Equity division, and is also the co-founder of Protective Technologies Capital, an investment firm specializing in sensing, protection and control solutions.

Related Stories